Brendan Curti
Overview
Explore the profile of Brendan Curti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gogas H, Ravimohan S, Datta A, Chhibber A, Munoz Couselo E, Diab A, et al.
NPJ Precis Oncol
. 2024 Jul;
8(1):150.
PMID: 39025948
In PIVOT IO 001 (NCT03635983), the combination of the investigational interleukin-2 agonist bempegaldesleukin (BEMPEG) with nivolumab (NIVO) had no added clinical benefit over NIVO monotherapy in unresectable/metastatic melanoma. Pre-defined baseline...
2.
Hassel J, Piperno-Neumann S, Rutkowski P, Baurain J, Schlaak M, Butler M, et al.
N Engl J Med
. 2023 Oct;
389(24):2256-2266.
PMID: 37870955
Background: Tebentafusp, a T-cell receptor-bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal melanoma. The...
3.
Le C, Vick L, Collins C, Dunai C, Sheng M, Khuat L, et al.
JCI Insight
. 2023 Sep;
8(18).
PMID: 37737264
Bystander activation of memory T cells occurs via cytokine signaling alone in the absence of T cell receptor (TCR) signaling and provides a means of amplifying T cell effector responses...
4.
Silk A, Curti B, Bryan J, Saunders T, Shih W, Kane M, et al.
Front Oncol
. 2023 Feb;
13:1108341.
PMID: 36845705
Introduction: High-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents...
5.
Bigelow E, Saria S, Piening B, Curti B, Dowdell A, Weerasinghe R, et al.
Cancer Inform
. 2022 Nov;
21:11769351221136081.
PMID: 36439024
Tumor mutational burden (TMB), a surrogate for tumor neoepitope burden, is used as a pan-tumor biomarker to identify patients who may benefit from anti-program cell death 1 (PD1) immunotherapy, but...
6.
Goldman J, Piha-Paul S, Curti B, Pedersen K, Bauer T, Groenland S, et al.
Clin Cancer Res
. 2022 Jun;
28(17):3709-3719.
PMID: 35699623
Purpose: Combination therapies targeting immunologic checkpoints have shown promise in treating multiple tumor types. We report safety and tolerability of MEDI0562, a humanized IgG1K OX40 mAb, in combination with durvalumab...
7.
Slingluff C, Lewis K, Andtbacka R, Hyngstrom J, Milhem M, Markovic S, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34599031
Background: Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing...
8.
Nathan P, Hassel J, Rutkowski P, Baurain J, Butler M, Schlaak M, et al.
N Engl J Med
. 2021 Sep;
385(13):1196-1206.
PMID: 34551229
Background: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic...
9.
Andtbacka R, Curti B, Daniels G, Hallmeyer S, Whitman E, Lutzky J, et al.
J Clin Oncol
. 2021 Aug;
39(34):3829-3838.
PMID: 34464163
Purpose: We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. Patients And Methods: In this multicenter, open-label, phase II study,...
10.
Clark J, Curti B, Davis E, Kaufman H, Amin A, Alva A, et al.
J Investig Med
. 2021 Feb;
PMID: 33542072
High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who...